Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026

B 38% response rate and 85% disease control rate at recommended dose in advanced/metastatic NRAS and BRAF Class II/III melanoma following failure of standard therapy…
posteditor
posteditor
Articles: 16137

Other News